With a Monday FDA green light for certain previously treated cervical cancer patients whose disease has worsened on or after chemotherapy, Keytruda became the first drug in its class to win a nod to treat those with the disease. Click here to view original web page at www.fiercepharma.com
A Pfizer documentary film about five patients living with cancer may have inspired more fanfare at Cannes Lions Health than it did in the eight months since its launch. The “This is Living With Cancer” film and its associated campaign was shortlisted for a pharma award at the annual ad festival and was heaped with[…]
Last year at this time, Pfizer’s $14 billion purchase of Medivation was being cited as a cautionary tale of M&A gone wrong, after one product of that deal—prostate cancer drug Xtandi—turned in disappointing data at the annual confab of the American Society of Clinical Oncology (ASCO). Pfizer also paid top dollar for Medivation for its[…]
Bluebird Bio and Celgene have built upon their already impressive early-stage clinical responses in advanced multiple myeloma, now confirming that their bb2121 CAR-T therapy extended progression-free survival to just shy of one year in a new set of phase 1 data. Click here to view original web page at www.fiercebiotech.com
Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion. Click here to view original web page at www.fiercepharma.com
Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it could soon reach beyond that group, thanks to data unveiled Sunday. Click here to view original web page at www.fiercepharma.com
Nektar Therapeutics’ much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo seem to have resulted in a lot of head-scratching. Click here to view original web page at www.fiercebiotech.com
Two pathways have long been of interest to researchers studying colon cancer: Notch and MAPK. But drugs designed to target either pathway have proven disappointing. Now a team of researchers in Germany has made a discovery that sheds light on those disappointments—and provides insight that could improve colon cancer treatment. Click here to view original[…]
Accent Therapeutics launched Friday with $40 million in the bank to develop cancer treatments based on epitranscriptomics, or the science around RNA structure, stability, function and translation in cell biology. Click here to view original web page at www.fiercebiotech.com
Memory transfer method could lead to new Alzheimer’s treatments by injecting RNA from one marine snail to another, researchers from the University of California in Los Angeles demonstrated that they could transfer memories. Click here to view original web page at www.fiercebiotech.com
Roche’s Tecentriq and Merck’s Keytruda have been associated with decreased survival in some patients with low levels of PD-L1, the biomarker those two drugs are designed to target. (Roche) Merck and Roche’s immunotherapies are each approved solo for certain previously untreated bladder cancer patients. Click here to view original web page at www.fiercepharma.com
Credit Suisse analyst Vamil Divan estimates that Keytruda could generate $6.6 billion in U.S. lung cancer sales. (Merck) Merck & Co. already controls a big part of the first-line non-small cell lung cancer market, and it likely just secured most of the rest of it. Click here to view original web page at www.fiercepharma.com